Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Abstract: The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).

Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Abstract: The present invention relates to a lyophilized composition comprising killed cancer cells with substantially retained immunogenicity and morphology, an intracellular cryopreservative such as trehalose and an extracellular cryopreservative such as polyvinylpyrrolidone. The present invention also relates to a process for the preparation of said lyophilized composition. The lyophilized composition of the present invention can be used for cancer immunotherapy.

Abstract: This invention discloses the process for lyophilization of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.

Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.

Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.

Abstract: The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation.

Abstract: The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition.

Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.

Abstract: The present invention relates to a stable oral pharmaceutical composition with improved solubility and bioavailability; comprising a taxoid, a solubilizer, a stabilizing agent, a surfactant(s), a solvent(s), and an oil wherein the concentration of taxoid is in the range of 0.1 to 10%.

Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.

Abstract: The present invention relates to novel hypoglycemic compounds of formula (1) and pharmaceutically acceptable salts thereof. The invention relates to novel amino acid derivatives of the formula (1), wherein, A is amino acid B is peptide bond R-NH- wherein R is defined in the specification.

Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.

Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Abstract: The present invention relates to a stable oral pharmaceutical composition with improved solubility and bioavailability; comprising a taxoid, a solubilizer, a stabilizing agent, a surfactant(s), a solvent(s), and an oil wherein the concentration of taxoid is in the range of 0.1 to 10%.

Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. wherein, A is defined as R3-R4 wherein R3 and R4 are together or independently defined as peptides having amino acids ranging from 1 to 10, B is chemical bond between peptide and substituted amine, R1, and R2 are as defined in specification.

Abstract: The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition.

Abstract: The present invention relates to novel hypoglycemic compounds of formula (1) and pharmaceutically acceptable salts thereof.